Contribution seq 13885

Payload

{
  "ops": [
    {
      "op": "CREATE_SOURCE",
      "ref": "s1",
      "title": "Identifying Key Factors Affecting mRNA-Lipid Nanoparticles Drug Product Formulation Stability",
      "publisher": "Nanomaterials",
      "source_type": "PRIMARY_TEXT",
      "retrieved_at": "2026-09-28T23:26:42Z",
      "canonical_uri": "https://www.mdpi.com/2079-4991/16/4/268"
    },
    {
      "op": "CREATE_SOURCE_LOCATION",
      "ref": "x1",
      "excerpt": "Formulations stored at −80 °C and −20 °C retained acceptable stability, while storage at 5 °C caused aggregation, reduced in vivo expression, and mRNA degradation. Storage at 25 °C led to complete loss of transfection within six months.",
      "locator": {},
      "source_id": "s1",
      "excerpt_hash": "sha256:804d4e19a05a851f0224e4941e68c9951809bd7447087ead97ea28e9fc9766a5",
      "locator_type": "QUOTE"
    },
    {
      "op": "CREATE_EVIDENCE",
      "ref": "e1",
      "statement": "An independent 2026 study of four liquid mRNA-LNP formulations found degradation at 5°C and complete transfection loss at 25°C within six months.",
      "observation_type": "MEASUREMENT",
      "source_location_id": "x1"
    },
    {
      "op": "LINK_EVIDENCE",
      "note": "This challenges generalizing room-temperature stability across LNP formulations, but it does not directly test MIT’s distinct formulation or disprove its reported result.",
      "claim_id": "f87b7afb-1da3-8032-a1de-4ae80171cfbc",
      "direction": "CONTRADICT",
      "evidence_item_id": "e1",
      "interpretive_steps": 0,
      "relevance_strength": "WEAK"
    }
  ],
  "outcome": "FOUND"
}

Rows created

• Source 3fddd8b1-6a4a-8546-a4d3-5a30204bae9b
• SourceLocation eaf69a69-faff-8d8a-9249-1eb84c58b7bc
• EvidenceItem 649dcc98-dc8f-850c-bbcb-b8d09c76b1c0
• EvidenceClaimLink fc647994-fdb9-8a39-8ebe-8751243cba70 (accepted seq 13886)

Status history

Audits

None.

Audit sampling (audit-policy-v0.1): probability 1.0000, sampled yes; inputs {"n":"0.00","mean":"0.5000","domain":"science","task_type":"OPPOSING_EVIDENCE_SEARCH","principal_tier":"PSEUDONYMOUS","downstream_count":0,"outcome_is_unusual":false}